oncology

Daiichi Sankyo takes oncology shift into next phase with new global business unit
Daiichi Sankyo takes oncology shift into next phase with new global business unit
Fierce Pharma
Daiichi Sankyo
oncology
Flag link:
$200M investment to advance clinical programs for Ambrx
$200M investment to advance clinical programs for Ambrx
MedCity News
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
Flag link:
Attacking pancreatic cancer with a novel immuno-oncology drug conjugate
Attacking pancreatic cancer with a novel immuno-oncology drug conjugate
Fierce Biotech
pancreatic cancer
antibody-drug conjugate
oncology
immuno-oncology
Flag link:
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
Endpoints
MD Anderson
biotech
funding
cancer
oncology
Flag link:
Oncology research mid-pandemic: Challenges may bring durable innovation
Oncology research mid-pandemic: Challenges may bring durable innovation
RAPS.org
oncology
clinical trials
R&D
pandemic
COVID-19
Flag link:
Large genomics study points the way to future cancer clinical trials
Large genomics study points the way to future cancer clinical trials
Fierce Biotech
genomics
oncology
cancer clinical trials
National Cancer Institute
Flag link:
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
Xconomy
SQZ Biotech
cancer
oncology
cell therapy
IPOs
Roche
Flag link:
Why Seattle Genetics Stock Jumped 24% in September
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Seattle Genetics
Merck
oncology
Tukysa
Flag link:
Blank check company merger creates cancer specialist Vincera
Blank check company merger creates cancer specialist Vincera
Pharmaforum
SPAC
Vincera
LifeSci Acquisition
oncology
cancer
Bayer
Flag link:
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Motley Fool
M&A
diagnostics
cancer diagnostics
cancer
oncology
Illumina
Grail
Flag link:
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
Flag link:
Exelixis, NBE join forces for discovery and development of ADCs for cancer
Exelixis, NBE join forces for discovery and development of ADCs for cancer
Pharmaceutical Business Review
Exelixis
NBE Therapeutics
antibody-drug conjugate
oncology
Flag link:
Astellas puts health inequality front and center in cancer innovation challenge's 5th year
Astellas puts health inequality front and center in cancer innovation challenge's 5th year
Fierce Pharma
Astellas
oncology
innovation
innovation challenges
Flag link:
Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies
Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies
Xconomy
Kinnate Biopharma
cancer
oncology
Flag link:
Gilead expands Tango alliance, continuing a busy year of cancer deals
Gilead expands Tango alliance, continuing a busy year of cancer deals
Biopharma Dive
Gilead Sciences
Tango Therapeutics
oncology
Flag link:
Achilles Heel of Immunotherapy-Resistant Cancers Revealed – and Eliminated – in Early Studies
Achilles Heel of Immunotherapy-Resistant Cancers Revealed – and Eliminated – in Early Studies
BioSpace
cancer
oncology
immunotherapy-resistant cancer
Flag link:
Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs
Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs
BioSpace
Tarveda Therapeutics
miniature drug conjugates
Pentarin
oncology
solid tumors
Flag link:
GSK’s John Fleming on rethinking oncology from the ground up
GSK’s John Fleming on rethinking oncology from the ground up
Pharmaforum
GSK
oncology
cancer
Flag link:
Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson
Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson
Endpoints
MD Anderson Cancer Center
Sanofi
clinical trials
oncology
Flag link:
Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic
Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic
BioSpace
Vor Biopharma
funding
stem cells
clinical trials
oncology
AML
Flag link:

Pages